RG-7351 explained

Class:Trace amine-associated receptor 1 (TAAR1) partial agonist
Synonyms:RG7351

RG-7351 is a trace amine-associated receptor 1 (TAAR1) partial agonist that is or was under development for the treatment of major depressive disorder.[1] [2] [3] [4] It reached phase 1 clinical trials for this indication in 2010. However, as of November 2023, no further recent development has been reported since July 2016. The drug was developed by Hoffmann-La Roche.

See also

Notes and References

  1. Web site: RG 7351 . AdisInsight . Springer Nature Switzerland AG . 5 November 2023 . 20 October 2024.
  2. Web site: Delving into the Latest Updates on RG-7351 with Synapse . Synapse . 19 September 2024 . 20 October 2024.
  3. Liu JF, Li JX . TAAR1 in Addiction: Looking Beyond the Tip of the Iceberg . Frontiers in Pharmacology . 9 . 279 . 2018 . 29636691 . 5881156 . 10.3389/fphar.2018.00279 . free .
  4. Book: Wu R, Liu J, Li JX . Behavioral Pharmacology of Drug Abuse: Current Status . Trace amine-associated receptor 1 and drug abuse . Adv Pharmacol . 93 . 373–401 . 2022 . 35341572 . 9826737 . 10.1016/bs.apha.2021.10.005 . 978-0-323-91526-7 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "RG-7351".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2025, A B Cryer, All Rights Reserved. Cookie policy.